The role of the neutrophil and free radicals in ischemic myocardial injury by Lucchesi, Benedict Robert et al.
1 Mel Cell Cardio121, 1241-1251 (1989) 
The Role of the Neutrophil and Free Radicals in Ischemic 
Myocardial Injury 
Benedict R. Lucchesi, Steven W. Werns’ and Joseph C. Fanton 
The LJnioersity of Michigan Medicine School, ‘Departments of Pharmacology, Internal Medicine and 
Patholopr2, Ann Arbor, Michigan, 48109, USA 
Introduction 
The association of coronary artery thrombosis 
with the onset of acute myocardial infarction 
has provided the rationale for the develop- 
ment of pharmacologic and/or physical 
methods for the restoration of coronary artery 
blood flow. The institution of pharmacologic 
methods for myocardial reperfusion has re- 
sulted in a reduction in mortality leading to 
acceptance of thrombolytic therapy as the 
standard approach to the management of pa- 
tients with an evolving acute myocardial in- 
farction [I]. It is a well established fact that 
prolonged myocardial ischemia leads to a 
time-dependent loss in the viability of my- 
ocardial cells in the jeopardized region of the 
heart and that the restoration of coronary 
artery blood flow is fundamental in order to 
arrest the progression of cell death and for the 
restoration of myocardial function. The rest- 
oration of blood flow is essential for repair of 
the reversible changes induced by ischemia 
and for the continued survival of the my- 
ocardial cells at risk of permanent damage. 
The reintroduction of oxygen at the time of 
reperfusion, however, may be detrimental to 
the reoxygenated myocyte as well as being 
beneficial. A number of recent reviews have 
been devoted to an examination of the ques- 
tion of whether reactive species of oxygen or 
oxygen radicals can contribute to the develop- 
ment of irreversible myocardial cell injury 
during the period of reperfusion [2, 3, 4, 51. 
The purpose of this editorial is to focus atten- 
tion on the potential role of the polymor- 
phonuclear leukocyte (PMN) as a determi- 
nant of the ultimate extent of irreversible 
myocardial injury after ischemia and reperfu- 
sion, and to call attention to those factors 
which modulate the inflammatory response to 
myocardial cell injury. 
Neutrophil-dependent mediation of 
vessel wall and myocyte injury 
The PMN possesses unique functions designed 
expressly for the defense of the host organism. 
Under certain conditions of altered physi- 
ology, the PMN may react in a manner that 
leads to tissue injury. The tissue damage re- 
sulting from myocardial ischemia activates a 
cascade of events which represents an in- 
flammatory response that occurs independ- 
ently of any improvement in myocardial re- 
oxygenation. The concept we wish to propose 
is that the inflammatory response and the 
invading leukocytes contribute to the ultimate 
extent of myocardial injury. Therefore, inter- 
ventions directed against the PMN or against 
the cytotoxic products produced by the invad- 
ing cells, should result in a reduction in the 
extent of tissue damage associated with my- 
ocardial ischemia and/or reperfusion. 
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Neutrophils invade a region of ischemic 
myocardium long before the transmural pro- 
gression of irreversible injury reaches the sub- 
epicardial myocardial region [q. Histologic 
studies by Sommers and Jennings [fl demon- 
strated that PMN were visible in the ischemic 
myocardium within 50 mins of reperfusion 
after coronary artery occlusion for 40 mins. 
Biochemical studies indicate that the infilt- 
ration of ischemic myocardium by PMN 
begins before reperfusion, and increases pro- 
gressively after reperfusion. The myocardial 
activity of myeloperoxidase, which correlates 
with the histologic extent of neutrophil in- 
filtration, exhibited a 6-fold increase after 90 
mins of coronary artery occlusion without 
reperfusion, and a 23-fold increase after 90 
mins of ischemia followed by 5 h of reperfusion 
[S]. PMN labeled with indium-1 11 have been 
employed to confirm that there is substantial 
accumulation of neutrophils within ischemic 
myocardium as early as 1 h after transient 
coronary artery occlusion for 40 or 90 mins 
[9]. Thus, reperfusion is essential in order to 
prevent further extension of ischemia-induced 
necrosis, but neutrophil-mediated injury 
would progress despite the restoration of blood 
flow to the myocardial region at risk. The 
factors involved in the initiation and the ter- 
mination of the myocardial inflammatory re- 
sponse are not understood in detail, but would 
serve as an interesting target for the develop- 
ment of new therapeutic interventions aimed 
at preventing an extension of tissue injury 
either during the ischemic period or shortly 
after reperfusion. A number of studies (re- 
viewed in [4]) have demonstrated that inter- 
ventions which limit neutrophil function or 
which interfere with the cytotoxic factors pro- 
duced by the infiltrating phagocytic cells can 
reduce ultimate infarct size resulting from a 
period of regional myocardial ischemia fol- 
lowed by reperfusion in the experimental 
animal. The role of the neutrophil as a con- 
tributor to myocardial injury in response to 
ischemia was suggested initially in 1971 [la]. 
More direct studies demonstrated that ulti- 
mate infarct size was reduced by 43% in the 
canine heart when neutropenic as compared 
to control animals were subjected to 90 mins of 
regional myocardial ischemia followed by re- 
perfusion for 6 h [II]; an observation which 
subsequently was confirmed by other inves- 
tigators using alternative means of inducing 
neutropenia [L?]. 
Additional support for the concept of neu- 
trophil mediated myocardial injury derives 
from the pharmacologic modulation of neu- 
trophil function during myocardial ischemia 
and reperfusion. Recognition of the mechan- 
ism of the protection afforded by ibuprofen on 
experimental myocardial injury was an im- 
portant step in addressing the role of the 
neutrophil in promoting reperfusion injury. In 
contrast to other inhibitors of cycle-oxygenase 
such as indomethacin and aspirin [13, 141, 
ibuprofen was noted to possess myocardial 
protective properties without altering regional 
myocardial blood flow or the relationship be- 
tween myocardial oxygen supply and demand 
[15, ISJ. An analysis of the results from the 
several studies mentioned, indicates that of the 
non-steroidal anti-inflammatory agents 
examined, only ibuprofen reduced neutrophil 
infiltration to the reperfused myocardium sug- 
gesting that the PMN contributes to the 
extension of the tissue injury [11, 121. Aspirin 
did not reduce infarct size or the in vitro 
neutrophil respiratory burst in response to 
stimulation of the PMN with C5a. This was in 
contrast to the response of the PMN in the 
presence of ibuprofen which prevented the 
complement induced activation of PMN and 
the production of oxygen radicals [14]. These 
studies indicate that ibuprofen, a non- 
steroidal anti-inflammatory agent, does not 
exert its protective effect upon the my- 
ocardium by inhibition of the cycle-oxygenase 
pathway of arachidonic acid metabolism or by 
altering those factors which restore the bal- 
ance between myocardial oxygen supply and 
demand. Further evidence for the role of the 
neutrophil as a mediator of reperfusion injury 
was derived from studies in which prostacyclin 
or a related analog, iloprost, as well as pros- 
taglandin El limited ultimate infarct size in a 
canine model of regional ischemia and reper- 
fusion. The mechanism of action was attri- 
buted to the ability of the prostanoids to 
inhibit the formation and release of neutrophil 
derived cytotoxic metabolites of oxygen [17, 
18, 191. The evidence derived from a number 
of studies is convincing and suggests that the 
pharmacologic inhibition of neutrophil func- 
tion correlates with the observed beneficial 
effects on ischemic myocardial injury. 
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The role of the Chemotactic factors in 
the activation and recruitment of 
neutrophils 
One of the most important sources of in- 
flammatory mediators involved in the acute 
inflammatory response is the complement sy- 
stem. Activation of the complement system 
has been shown to generate a potent neutro- 
phi1 chemotactic factor, Csa, that plays an 
important role in the recruitment and activ- 
ation of neutrophils, to sites of tissue injury. 
Proteolytic enzymes from both plasma and 
cell sources may also react with individual 
complement components resulting in the 
formation of inflammatory mediators, without 
causing generalized activation of the comple- 
ment cascade. The presence of a tissue pro- 
tease in ischemic myocardium was initially 
suggested as being involved in cleaving the 
third component of complement into chemo- 
tactically active fragments that may stimulate 
the attraction of neutrophils to the my- 
ocardium [ZO]. Recent evidence indicates that 
the cardiac lymphatic drainage from the 
ischemic myocardium contains molecules of 
mitochondrial and subcellular origin that are 
bound to C,, which may activate the comple- 
ment cascade, promote the release ofleukotac- 
tic anaphylatoxins, and stimulate the migra- 
tion of PMN’s to sites of tissue injury [ZZ]. The 
central role of the complement system in the 
recruitment and activation of the PMN within 
the ischemic myocardium is illustrated by the 
finding that depletion of complement with 
cobra venom factor significantly reduced 
PMN infiltration into ischemic myocardium 
and resulted in a decrease in tissue injury 
associated with regional ischemia and reperfiu- 
sion [IO, 221. Complement derived products 
can exacerbate ischemic tissue injury and car- 
diac dysfunction by mechanisms which are 
independent of the presence of neutrophils. 
Neutrophil independent injury by comple- 
ment may be associated with the vascular 
actions of the C3a, C4a, and C5a, known to 
enhance vascular permeability and alter vessel 
tone as well as through the formation of the 
cytolytic membrane attack complex (C5b-9) 
which can result in the production of trans- 
membrane channels and facilitate the influx of 
extracellular calcium and disruption of my- 
ocyte function [23]. 
Recent studies have also shown that endo- 
thelial cells may be an important source of a 
specific neutrophil chemotactic factor [24]. 
Treatment of endothelial cells with either 
interleukin-a (IL-l) or tumor necrosis factor a 
(TNF-a) will induce the synthesis and secre- 
tion of a neutrophil chemotactic factor similar 
in structure to a human monocyte derived 
neutrophil activating factor (NAF). NAF will 
not only promote neutrophil chemotaxis but 
also induce an increase in intracellular cal- 
cium, oxidative burst, and granule exocytosis 
via a GTP-binding protein dependent path- 
way; a response similar to that observed with 
other chemotactic peptides (e.g., Csa, formyl- 
methionyl-leucyl-phenylalanine) [25]. The 
potential role that endothelial cell derived 
mediators may play in activating neutrophils 
following ischemic injury has not been inves- 
tigated but represents a potentially important 
mechanism for the activation of circulating 
neutrophils in ischemic myocardium. 
The role of adherence-promoting cell 
surface glycoprotein complexes 
The surface of the PMN exhibits a family of 
heterodimeric glycoproteins possessing acom- 
mon B subunit of 95 kDa (CD18) associated 
noncovalently with separate ct subunits of 177, 
165 and 150 kDa which are designated as 
LFA-1 (CD1 la), Mol or Mac-l (CD1 lb) and 
gp150 (CDllc) respectively. The Mol gly- 
coprotein heterodimer is involved in the pro- 
cess of cellular adhesion and serves as the 
receptor for C3bi opsonized particles. It is 
believed that distinct stimuli mobilize Mol 
from intracellular sites and lead to its ex- 
pression on the cell surface. Mol participates 
in adherence of the leukocyte to the endo- 
thelial cell and to other PMN’s as well as in 
chemotaxis and spreading on cell surfaces. An 
increase of up to P-fold in Mol cell-surface 
expression has been observed therefore sug- 
gesting that at least 50% of the total popul- 
ation of Mol receptors is located intracellular- 
ly. The increased expression of Mol would 
increase neutrophil adherence to cell surfaces 
and facilitate chemotaxis. The increase in 
Mol receptor expression is coupled to the 
release of neutrophil gelatinase which partici- 
pates in the degradation of connective tissue 
thereby allowing for the passage of neutrophils 
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through capillary walls and into the extra- 
vascular space. The up-regulation of Mol, 
which is the receptor for CSbi, would allow for 
enhanced recognition and attachment to 
endothelial surface which have been “opso- 
nized” (Fig. 1). Prior endothelial injury re- 
sulting from ischemia and reoxygenation pro- 
motes neutrophil adherence to the cell surface. 
PMN adherence may be due to the uncover- 
ing on the endothelium of specific cell surface 
molecules that directly interact with neutro- 
phi1 CD18 molecules or receptors for C3bi; the 
latter serving as the receptor for Mol ex- 
pressed on the surface of the neutrophil. In 
vitro studies have demonstrated enhanced 
binding of neutrophils to endothelial surfaces 
secondary to the interaction of neutrophil 
CD 18 molecules with intercellular adhesion 
molecule-l (ICAM-1) on the endothelial cell 
membrane [2q. Enhanced ICAM- 1 ex- 
pression on endothelial cell surface, can be 
induced by multiple inflammatory mediators 
including bacterial endotoxin and the 
cytokines IL- 1, interferon-y (INF-y), and 
TNF-a [271. Similarly, a distinct endothelial 
leukocyte adhesion molecule (ELAM-1) that 
promotes neutrophil binding to endothelium 
can be transiently induced by specific 
cytokines [28, 291. Whether similar increased 
expression of ELAM-1, ICAM- or ICAM- 
like molecules occurs in ischemic endothelium 
is not known, but potentially may play an 
important role in leukocyte localization to 
ischemic myocardium. 
These studies in conjunction with the recent 
observation that specific cytokines will induce 
the synthesis and secretion of a neutrophil 
chemotactic factor by endothelial cells pro- 
vide further evidence for an active role of the 
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FIGURE 1. Schematic representation of the leukocyteendothelial cell interaction in response to injury. Endothelial 
injury secondary to ischemia and reoxygenation promotes neutrophil adherence to the cell surface. Specific endothelial 
cell surface molecules interact with neutrophil CD18 glycoprotein adhesion promoting receptor. C3bi derived from the 
activation of the complement system in response to injury serves to “opsonize” the endothelial cell and is the receptor for 
Mol expressed on the surface of the neutrophil. Expression of the neutrophil CD1 lb/CD18 heterodimeric complex 
(Mol) on the plasma membrane of the neutrophil is a response to inflammatory stimuli (C5a, leukotrienes, 
thromboxane, etc.). 
Neutrophil CD18 molecules can interact with intracellular adhesion molecule-l (ICAM-1) on the endothelial cell 
membrane thereby serving as an alternate mechanism for the attachment of inflammatory cells to a target tissue. 
ICAM- and ELAM-1 (endothelial leukocyte adhesion molecule) are expressed in response to a variety of cytokines 
acting on the endothelial cell. In addition, the cytokines, interleukin-I (IL-l), tumor necrosis factor (TNF) and 
interferon y (IFN v) will induce synthesis and secretion of a neutrophil chemotactic factor by endothelial cells thereby 
permitting the endothelium to participate actively in the recruitment and attachment of inflammatory cell mediators to 
the tissue which has been “targeted” as a result of injury. Whether or not the sequence of event described occurs in the 
heart which has been subjected to ischemia and reperlusion remains a topic of further study. 
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tivation and recruitment to ischemic tissues 
rather than a “passive” participant in the 
interaction of inflammatory cells with the vas- 
cular wall. The ability of endothelial cells and 
PMN’s to attach to each other is required for 
an effective chemotactic response and for some 
forms of neutrophil mediated vascular injury 
and represents an important initial step in the 
sequence of events associated with the acute 
inflammatory response. A variety of agonists 
involved in acute inflammation, including 
thrombin, PAF and leukotriene Cd, are 
known to facilitate the adherence of neutro- 
phils to the endothelial surface. The neutro- 
phi1 CD18 glycoprotein molecules may part- 
icipate in other functions aside from cell-cell 
adhesion and chemotaxis. The glycoproteins 
may be important in the transduction of sig- 
nals from the cell surface to intracellular enzy- 
matic regulatory systems as suggested by the 
presence of an extensive intracellular domain 
providing sites for interaction with 
cytoplasmic proteins and cytoskeletal 
elements. 
Monoclonal antibodies specific for either 
the a or B subunits of Mol have been demon- 
strated to inhibit certain neutrophil/monocyte 
functions: (a) the binding of C3bLopsonized 
particles, and (b) adhesive interactions of neu- 
trophils and monocytes including neutrophil 
aggregation, monocyte/neutrophil adhesion 
and spreading on substrates (including vas- 
cular endothelium), and chemotaxis. The 
leukocytes of patients who are genetically defi- 
cient in their expression of the Mol glyco- 
protein exhibit an impairment ofC3bi-particle 
binding and leukocyte adhesive interactions. 
It is suggested therefore that the Mol gly- 
coprotein has a domain which functions as the 
plasma membrane receptor for C3bi(CR3). 
The critical role of Mol in the inflammatory 
response of activated neutrophils is suggested 
by the inhibitory effect of anti-MO1 mono- 
clonal antibody on neutrophil-mediated endo- 
thelial cell injury in a rat lung model of adult 
respiratory distress syndrome [30] and 
neutrophil-dependent vascular injury in skin 
[.?I]. A monoclonal antibody (904) that binds 
to the Mol leukocyte cell adhesion-promoting 
glycoprotein, CD1 1 b/CD1 8, was admini- 
stered to open chest anesthetized dogs 45 
minutes after the induction of regional my- 
ocardial ischemia. Ischemia was produced by 
occluding the left circumflex coronary artery 
for 90 mins followed by reperfusion for 6 
hours. There was no difference between con- 
trol and antibody treated groups with respect 
to arterial blood pressure, heart rate or coron- 
ary blood flow. Administration of antibody 
produced no observable effect on circulating 
neutrophil counts, suggesting that antibody- 
bound neutrophils were not cleared from the 
circulation. The mean size of myocardial in- 
farct expressed as percentage of the area at 
risk of infarction that resulted was reduced by 
46% with anti-MO1 treatment (Fig. 2). The 
area at risk of infarction was similar between 
groups. Accumulation of neutrophils within 
the myocardium was reduced significantly 
with anti-MO1 antibody treatment [32]. 
Similar protective effects were obtained in 
subsequent studies with the anti-MO1 F(ab’)P 
fragments in which antibody treatment was 
maintained for 48 h into the repetfusion 
period and infarct size determined at 72 h 
postreperfusion [33]. Furthermore, regional 
myocardial blood flow determinations indi- 
cated that both groups had equal degrees of 
ischemia in the inner 2/3 of the myocardium 
during the period of coronary artery occlu- 
sion. The results with the anti-MO1 antibody 
indicate that the adhesive interactions of the 
neutrophil may play a central role in neutro- 
phi1 mediated damage and that inhibition of 
neutrophil adhesive interactions can reduce 
the extent of irreversible myocardial damage 
associated with reperfusion. The results are in 
accord with previously mentioned studies in 
which myocardial reperfusion injury was re- 
duced by a variety of interventions which 
shared the one common property of altering 
the ability of the neutrophil to react with its 
target tissue: the ischemically altered my- 
ocardial cell [14, 12, IS, 191. 
The data from the above mentioned studies 
show that inhibition of neutrophil adhesion 
reduces the myocardial reperfusion injury and 
provided additional evidence for the import- 
ant role of inflammatory cells in extending 
myocardial injury beyond that caused by the 
ischemic process itself. The data also support 
the hypothesis that a significant number of 
myocardial cells in the region at risk are viable 
after a 90-min inschemic period, but then 
progress to an irreversible state of injury upon 
reperfusion and the accumulation of polymor- 
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EFFECT OF ANTI-Mel ANTIBODY ON MYOCARDIAL INFARCT SIZE 
6 hours i 72 hours 
Control- I Anti-MO-1 Control-2 Anti-MO1 
F (ob’)? 
FIGURE 2. Myocardial infarct size in the canine heart expressed as a percentage of the risk region in a control group 
and in a group of animals treated with a murine monoclonal anti-MO I antibody. The two bars on the left represent the 
results from a study in which coronary artery occlusion was maintained for 90 mins and reperfusion lasted for 6 hours 
after which infarct size was determined. Treatment consisted of the administration of I mg/kg intravenously of Mol 
antibody given over IO mins starting 45 mins after coronary artery occlusion. Inhibition of the Mel receptor by the 
anti-MO1 antibody treatment resulted in a 46% reduction in myocardial infarct size as compared to a vehicle treated 
group. 
The two bars on the right represent data taken from a similar study in which the F(ab’2) fragment of the Mol 
antibody was used in a dosing regimen of 1 mg/kg over 5 minutes starting 45 mins after coronary artery occlusion with 
repeated 0.5 mg/kg doses at 12, 24, 36 and 48 h after reperfusion. Infarct size was determined 24 h later (72 h after 
reperfusion). Despite the withdrawal of the antibody treatment, infarct size was reduced when determined at 72 h post- 
reperfusion. The data suggest that a sustained reduction in infarct size can be achieved by the modulation of neutrophil 
reactivity. 
phonuclear leukocytes. Recent studies from 
this laboratory [34] have identified a specific 
“time window” in which neutrophils partici- 
pate in the extension of myocardial infarction 
after ischemia and reperfusion. The inhibition 
of neutrophil activation and accumulation in 
the myocardium over a prolonged period of 
time (< 48 h) is necessary to ensure a 
beneficial effect on the ultimate extension of 
irreversible myocardial injury. Therefore, in- 
terventions which have limited pharmacologic 
half-lives while effective over brief periods of 
observation, may not show protective benefits 
if given in a single initial dose while assessment 
of infarct size is made at a period far removed 
from the point of administration of the treat- 
ment under study. Failure to recognize the 
pharmacokinetic properties of various inter- 
ventions along with the dynamic and pro- 
gressive nature of myocyte injury may account 
for many of the discordant results in the 
literature. 
Neutrophils, oxygen radicals and 
myocardial b&u-y due to ischemia and 
reperfiwion 
The observations enumerated above provide 
support for the hypothesis that under some 
conditions of regional myocardial ischemia 
and reperfusion, neutrophils adhere to the 
vessel wall at sites of inflammation and release 
toxic products capable of damaging the adja- 
cent endothelium as well as myocytes within 
the reperfused region. It is well recognized 
that neutrophils can release cytotoxic pro- 
ducts extracellularly without themselves un- 
dergoing destruction. Neutrophils can release 
a variety of mediators capable of promoting 
tissue injury, including proteolytic enzymes, 
Ischemic Myocardid injury 1247 
platelet-activating factor, arachidonic acid 
metabolites and activated species of oxygen. 
Among the last mentioned group of neutro- 
phi1 derived products, superoxide anion (0;)) 
hydrogen peroxide (HzOz), hydroxyl radical 
(*OH) and hypochlorous anion (OCI-) may 
be considered to be the most significant 
cytotoxic products derived from the metabol- 
ism of molecular oxygen upon perturbation of 
the PMN. It is proposed that the generation of 
the cytotoxic metabolites of oxygen generated 
within the micro environment formed be- 
tween the adherent activated PMN’s and 
altered endothelial cells leads to an increase in 
vascular permeability and myocyte damage 
which is “explosive” upon reperfusion as neu- 
trophils are directed and attracted to the 
reperfused region under the influence of the 
local accumulation of chemoattractants. Dur- 
ing an extended period of regional ischemia of 
40 mins or longer [9], the stage is set for the 
neutrophil mediated inflammatory response 
and injury which involves cells which were 
normal or reversibly injured and is accelerated 
by reperfusion of the ischemic region. Thus, 
reperfusion injury involves cells which were 
viable or recoverable up until the time that 
reperfusion was instituted. It is suggested that 
the extension of cell death upon reperfusion of 
the ischemic myocardium is mediated, in part, 
by the neutrophil derived cytotoxic products 
of oxygen metabolism. It should be obvious 
that in the absence of reperfusion, all cells 
which are ischemic will undergo irreversible 
changes and that reperfusion is essential for 
survival of the myocytes which are viable up 
until the time of reperfusion. However, a 
portion of the still viable myocardial cells will 
undergo further injury due to the cytotoxic 
actions of the reactive species of oxygen. 
The first suggestive evidence for the in viva 
participation of oxygen radicals in myocardial 
reperfusion injury developed from the work of 
Jolly et al. [35J who demonstrated that the 
administration of superoxide dismutase plus 
catalase to anesthetized dogs subjected to a 
9O-min interval of regional myocardial 
ischemia followed by reperfusion reduced ulti- 
mate infarct size when the scavenger enzymes 
were administered either before the induction 
of regional myocardial ischemia or 1.5 mins 
before myocardial reperfusion. In contrast, 
the enzymes were without beneficial effect if 
they were infused 40 mins after reperfusion 
had been instituted. These observations sug- 
gested that an extension of myocardial injury, 
in addition to that associated with the 
ischemia-induced myocardial cell death, was 
occurring very early during reperfusion and 
that the myocardial damage could be at- 
tenuated by pretreatment with the free- 
radical metabolizing enzyme, superoxide dis- 
mutase. Subsequent studies have demon- 
strated that superoxide dismutase without the 
addition of catalase was equally elective in 
preventing the extension of myocardial injury, 
thereby implicating superoxide anion as the 
primary mediator of the myocardial damage 
associated with reperfusion. The relatively 
short pharmacologic half-life (6-10 mins) of 
superoxide dismutase represents a drawback 
to the study of the scavenger in experimental 
protocols which extend several days post- 
reperfusion. Neutrophil chemoattraction to 
the ischemically injured myocardium and the 
local formation of neutrophil derived reactive 
species of oxygen, will continue to effect a 
cytotoxic influence upon the viable my- 
ocardial cells in the reperfused tissue. The free 
radical induced injury, therefore, occurs soon 
after reperfusion and is sustained, until yet to 
be elucidated mechanisms bring about an 
arrest to the damaging effects of the inflamma- 
tory response. 
The inability of recent studies to demons- 
trate a cardioprotective effect of superoxide 
dismutase may be attributable to the long 
interval between the administration of the 
enzyme, which has a brief half-life (S-10 
mins), and the assessment of infarct size 4 days 
[363 or 7 days [37J later. The validity of this 
concept was examined using a modified form 
of superoxide dismutase in which the enzyme 
is conjugated to polyethylene glycol (PEG- 
SOD) [%?I. The conjugated form of SOD has 
a pharmacologic half-life of 30 h. Significant 
plasma SOD activity can be demonstrated in 
the dog up to 7 days after a single intravenous 
administration of 1000 U/kg of PEG-SOD. 
Two protocols differing in the mode of admini- 
stration and duration of the reperfusion inter- 
val were used. Dogs were subjected to occlu- 
sion of the circumflex coronary artery for 90 
mins, then reperfused for either 6 h (Protocol 
A) or for 4 days (Protocol B) . The animals 
received either polyethylene glycol conjugated 
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to albumin (PEG-ALB) or PEG-SOD 1000 regression line describing the relationship be- 
U/kg. In Protocol A, treatment was admini- tween the extent of irreversible myocardial 
stered starting 15 mins before coronary artery injury and collateral blood flow was shifted 
occulusion and continued for 2 h, terminating downward (analysis of covariance, P = 0.0 17) 
15 mins after reperfusion. Infarct size was in the group of animals treated with 
determined 6 h later. In Protocol B, the conju- PEG-SOD. Using the mean collateral blood 
gated proteins were given 15 mins before flow to the inner two thirds of the ischemic 
reperfusion and ended simultaneously with myocardium as a covariate, infarct size ex- 
reperfusion. Infarct size was measured after 4 pressed as a percentage of the area at risk was 
days. A significant reduction in myocardial smaller for the PEG-SOD treated group than 
infarct size, expressed as a percent of the area for the PEG-ALB treated group (P < 0.05). 
at risk, was observed in Protocol A in the The data demonstrate that unlike unmodified 
group of animals which received PEG-SOD superoxide dismutase [36,37J, PEG-SOD can 
as compared to the PEG-ALB treated con- achieve a reduction in ultimate infarct size 
trols. Likewise, in the extended protocol in when quantitation of myocardial injury is 
which infarct size was determined 4 days after done after 4 days of reperfusion, a time when 
reperfusion, the PEG-SOD treated group ex- the plasma superoxide dismutase activity is 
hibited a significant reduction in ultimate maintained well above that found in the 
infarct size (Fig. 3). Hemodynamic variables PEG-ALB control group. These data are con- 
did not differ during the period of coronary sistent with studies noted above demonstrat- 
artery occlusion. The respective collateral ing the necessity to suppress neutrophil func- 
Aood flows to the inner two thirds of ischemic tions up to 48 h to effect a reduction in infarct 
myocardium determined 60 mins after occlu- size at 72 h 1341 and support the hypothesis 
sion did not differ between the groups. Infarct that there exists a critical “time window” 
size was related inversely to collateral blood during which antineutrophil and/or antioxi- 
flow in the PEG-ALB treated group. The dant therapy must be maintained to effect a 









FIGURE 3. The effect of polyethylene-glycol conjugated superoxide dismutase (PEGSOD) on myocardial infarct 
size due to a 90 min occlusion and subsequent reperfusion of the left circumflex coronary artery in the canine heart. A 
single dose of PEG-SOD of 1000 U/kg was administered before reperfusion in each of the two studies. The control 
groups received polyethylene-glycol conjugated to albumin so that the administered amount of PEG and conjugated 
protein was comparable in all animals. Infarct size in the two groups ofdogs depicted on the left was determined after 6 
h of reperfusion. The two groups of dogs shown on the right had infarct measurements made 4 days after reperfusion. 
The data illustrate that PEG-SOD with a 30 h plasma half-life is able to provide sustained protection against the 
cytotoxic effects of superoxide anion derived in part from the infiltration of inflammatory cells to the reperfused 
myocardium. 
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reduction in the ultimate extent of the in- 
farcted myocardium following periods of 
ischemia and reperfusion. The potential 
beneficial effect of PEG-SOD, as compared to 
the native form of the enzyme, is demon- 
strated in a recently published study [3!?] in 
which the sustained presence of the oxygen 
radical scavenger prevented rather than de- 
layed the development of irreversible my- 
ocardial cell injury. 
The superior efficacy of PEG-SOD com- 
pared to the native enzyme may relate to both 
its continued presence in the circulation and 
its ability to adhere to the surface of the 
vascular endothelium. Polyethylene glycol 
conjugation of superoxide dismutase enhances 
cell association and uptake of the enzyme in a 
manner that renders the vascular endothelium 
more oxidant resistant. The vulnerability of 
the endothelium to injury from reactive 
species of oxygen may be related to a number 
of factors, which include the anatomical prox- 
imity to activated and invading inflamma- 
tory cells and localization of xanthine oxidase 
activity within endothelial cells. Vascular 
endothelial cells subjected to an ischemic 
equivalent of anoxic incubation followed by 
reoxygenation become effective generators of 
oxygen free radicals as determined by electron 
paramagnetic resonance measurements with a 
spin trap agent, DMPO [40]. Superoxide dis- 
mutase or catalase abolished the radical sig- 
nal, suggesting that oxygen is sequentially 
reduced from 0; to Hz02 to *OH. Attenu- 
ation of the free radical signal by oxypurinol 
suggested that xanthine oxidase was a major 
source of the superoxide anion. It is conceiv- 
able that upon reperfusion of the ischemic 
myocardium, the endothelial cells as well as 
the adherent and infiltrating neutrophils may 
provide the initial source of cytotoxic species 
of reduced oxygen and that the subsequent 
inflammatory process involving the continued 
migration and accumulation of PMN’s to the 
injured myocardium provides a sustained 
source of oxygen radicals which diminished 
with time as reparative processes supervene. 
Regardless of the cellular site for their gen- 
eration (endothelial cell, neutrophil, or other 
cellular loci) the role of reactive species of 
oxygen in mediating cellular injury associated 
with reperfusion has gained wide support 
through a number of studies which have been 
reviewed recently [5, 41, 4, 3]. The literature 
has not always agreed with the concept that 
reperfusion of the ischemic myocardium may 
result in an extension of injury beyond that 
which has resulted from the ischemic insult 
itself It is our belief that the inconsistent 
observations among laboratories are related to 
important differences in the models employed 
with respect to instrumentation of the heart in 
chronic animal studies, the duration of occlu- 
sion (90 mins vs 40 min or 3 h), and the 
duration therapy relative to the duration of 
reperfusion. Superoxide dismutase, neutrophil 
depletion, and ibuprofen, which inhibits 
neutrophil-mediated injury, did not limit the 
extent of myocardial injury in studies that 
employed a coronary occlusion lasting 3 h [4?, 
43,441. Most important is the need to consider 
the pharmacokinetic properties of the respec- 
tive interventions employed to modify the 
extent of reperfusion injury in view of the fact 
that the neutrophil mediated component of 
reperfusion injury may be operative for 
several days [34]. Previously reported negative 
studies with native SOD may be related to the 
short half-life of its free radical scavenging 
capacity, which compromises the chances of 
observing a protective effect after 4 days of 
reperfusion. On the other hand, protocols 
which involve a 40 min ischemic interval ma) 
not be of sufficient duration to allow for re- 
cruitment of the inflammatory response. 
Thus, the resulting tissue damage may be 
related primarily to the ischemic insult. In the 
latter instance, it would be difficult to detect a 
beneficial response to an intervention directed 
against cell damage related to reperfusion 
which we believe is mediated in large part by 
the cytotoxic action of invading inflammatory 
cells. 
The progression of tissue injury and cell 
death is a time dependent phenomenon invol- 
ving cooperative interactions resulting in the 
activation of the complement system, form- 
ation of chemotactic factors, cytokine 
mediated stimulation of the endothelium and 
expression of cell surface adhesive receptors, 
all of which play an active role in mediating 
the inflammatory response. The complex se- 
quence of events, once initiated, are likely to 
continue, albeit for a limited duration which 
may be measured in days rather than minutes. 
The answer to the question of whether inter- 
1250 B. R. Lucchemi et al. 
ventions administered before or at the time of 
reperfusion can limit the ultimate extent of 
tissue injury remains unanswered. Efforts must 
be devoted towards eliminating differences 
among those studies which report disparate 
results. This essay has been developed with the 
intent of calling attention to some of the 
multiple factors which can mediate tissue in- 
jury. It is our hope that the reader will be 
stimulated toward further study, especially 
concerning those immunologic aspects of the 
problem which have as yet not been explored 
thoroughly in the setting of myocardial reper- 
fusion injury. 
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